-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Lisata Therapeutics (NASDAQ:LSTA) and Ontrak (NASDAQ:OTRK) Head-To-Head Contrast
Lisata Therapeutics (NASDAQ:LSTA) and Ontrak (NASDAQ:OTRK) Head-To-Head Contrast
Lisata Therapeutics (NASDAQ:LSTA – Get Rating) and Ontrak (NASDAQ:OTRK – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Profitability
This table compares Lisata Therapeutics and Ontrak's net margins, return on equity and return on assets.
Get Lisata Therapeutics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
| Ontrak | -279.90% | -183.58% | -92.71% |
Valuation & Earnings
This table compares Lisata Therapeutics and Ontrak's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.30 |
| Ontrak | $84.13 million | 0.26 | -$37.14 million | ($3.38) | -0.25 |
Institutional & Insider Ownership
6.0% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 49.8% of Ontrak shares are owned by institutional investors. 2.2% of Lisata Therapeutics shares are owned by insiders. Comparatively, 46.6% of Ontrak shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and target prices for Lisata Therapeutics and Ontrak, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Ontrak | 0 | 0 | 0 | 0 | N/A |
Lisata Therapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 312.09%. Ontrak has a consensus price target of $2.27, suggesting a potential upside of 171.46%. Given Lisata Therapeutics' higher possible upside, equities research analysts clearly believe Lisata Therapeutics is more favorable than Ontrak.
Risk and Volatility
Lisata Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500.
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
About Ontrak
(Get Rating)
Ontrak, Inc. engages in the provision of data analytics based behavioral health management and integrated treatment services to health plans. It offers services through its Ontrak platform solution, which is designed to improve member health, and at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The company was founded by Terren S. Peizer in February 2003 and is headquartered in Santa Monica, CA.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Lisata Therapeutics (NASDAQ:LSTA – Get Rating) and Ontrak (NASDAQ:OTRK – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
利莎塔治療 (NASDAQ: LSTA — 獲得評分) 和安特拉克 (NASDAQ: OTRK — 獲得評級) 都是小型公司, 但哪個是更好的投資?我們將根據兩家企業的收益，盈利能力，風險，分析師建議，股息，估值和機構所有權的實力進行比較。
Profitability
盈利
This table compares Lisata Therapeutics and Ontrak's net margins, return on equity and return on assets.
此表格比較了利莎塔治療和安特拉克的淨利潤率，股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
| Ontrak | -279.90% | -183.58% | -92.71% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 利莎塔治療 | N/A | -29.53% | -27.96% |
| 昂特拉克 | -279.90% | -183.58% | -92.71% |
Valuation & Earnings
估值及收益
This table compares Lisata Therapeutics and Ontrak's gross revenue, earnings per share (EPS) and valuation.
此表格比較利莎塔治療和安特拉克的總收入，每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.30 |
| Ontrak | $84.13 million | 0.26 | -$37.14 million | ($3.38) | -0.25 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 利莎塔治療 | N/A | N/A | -27.47 百萬美元 | (十二二三元) | -0.30 |
| 昂特拉克 | 八千四百一十三萬美元 | 0.26 | -37.5 億美元 | (三百三十八元) | -0.25 |
Institutional & Insider Ownership
機構和內幕所有權
6.0% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 49.8% of Ontrak shares are owned by institutional investors. 2.2% of Lisata Therapeutics shares are owned by insiders. Comparatively, 46.6% of Ontrak shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
利莎塔治療學股份的 6.0% 由機構投資者擁有。相比之下，49.8％ 的 Ontrak 股份由機構投資者擁有。利薩塔治療股份的 2.2％ 由內部人士擁有。相比之下，安特拉克股份的 46.6％ 由內部人士擁有。強大的機構擁有權表明，大型資金經理，捐贈基金和對沖基金認為股票有望實現長期增長。
Analyst Ratings
分析師評級
This is a breakdown of current ratings and target prices for Lisata Therapeutics and Ontrak, as provided by MarketBeat.
這是利莎塔治療和 Ontrak 的當前評分和目標價格的細分，由 MarketBeat 提供。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Ontrak | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 利莎塔治療 | 0 | 0 | 2 | 0 | 3.00 |
| 昂特拉克 | 0 | 0 | 0 | 0 | N/A |
Lisata Therapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 312.09%. Ontrak has a consensus price target of $2.27, suggesting a potential upside of 171.46%. Given Lisata Therapeutics' higher possible upside, equities research analysts clearly believe Lisata Therapeutics is more favorable than Ontrak.
利莎塔治療目前的一致價格目標為 15.00 美元，表明潛在的上行空間為 312.09％。安特拉克的一致價格目標為 2.27 美元，表明潛在的上行空間為 171.46％。鑑於 Lisata 治療的可能較高的上行空間，股票研究分析師清楚地認為 Lisata 治療比 Ontrak 更有利。
Risk and Volatility
風險及波動性
Lisata Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500.
利薩塔治療的測試版為 1.04，這意味著其股票價格比標普 500 高出 4％ 的波動性。相比之下，安特拉克的測試版為 2.16，這意味著其股票價格比標普 500 高出 116％ 的波動性。
About Lisata Therapeutics
關於利莎塔治療
(Get Rating)
(取得評分)
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
利莎塔治療, 公司. 開發生物製藥.它致力於治療晚期實體瘤和其他重大疾病的創新療法的發現，開發和商業化。它旨在通過激活一種新穎的吸收途徑來改變腫瘤微環境，從而使抗癌藥物更有效地穿透實體腫瘤。該公司總部位於新澤西州姥嶺。
About Ontrak
關於安達
(Get Rating)
(取得評分)
Ontrak, Inc. engages in the provision of data analytics based behavioral health management and integrated treatment services to health plans. It offers services through its Ontrak platform solution, which is designed to improve member health, and at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The company was founded by Terren S. Peizer in February 2003 and is headquartered in Santa Monica, CA.
Ontrak, Inc. 致力於為健康計劃提供基於數據分析的行為健康管理和綜合治療服務。它通過其 Ontrak 平台解決方案提供服務，該解決方案旨在改善會員健康狀況，同時為行為健康狀況導致或加劇共存的醫療條件而降低服務不足的人群的成本。該公司由泰倫 ·S· 佩澤於 2003 年 2 月成立，總部位於加利福尼亞州聖莫尼卡。
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收利莎塔治療日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Lisata 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧